Kura Oncology, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of precision medicines for oncology. The company's core business model revolves around identifying and targeting specific molecular pathways and genetic mutations that drive cancer proliferation, aiming to provide more effective treatments for patients with high unmet medical needs.
Kura's flagship product is KOMZIFTI (ziftomenib), an oral, small molecule menin inhibitor that received FDA approval for the treatment of genetically defined acute myeloid leukemia (AML). Beyond its lead asset, the company is advancing a robust clinical pipeline that includes darlifarnib (KO-2806), a next-generation farnesyl transferase inhibitor (FTI). Darlifarnib is being evaluated in combination with other targeted therapies for large solid tumor indications, such as clear cell renal cell carcinoma (ccRCC) and HRAS-mutant tumors.
Financially, Kura Oncology has historically operated as a clinical-stage entity, generating revenue primarily through strategic collaborations, milestone payments, and licensing agreements. A key driver of its recent revenue is a strategic partnership with Kyowa Kirin, which provides significant non-dilutive funding and supports the global commercialization of ziftomenib outside the United States, while Kura retains commercial rights in the U.S. As the company transitions into a fully commercial-stage organization following the approval of KOMZIFTI, direct product sales are expected to become its primary revenue source. Headquartered in San Diego, California, Kura Oncology leverages its deep expertise in tumor biology and genetic analysis to maintain a competitive edge in the precision oncology landscape.
